STICH is one such protocol: STop the SGLT2 inhibitor, Inject bolus insulin, Consume 30 g carbohydrates and Hydrate
[2] At its May 2025 meeting, the WHO Advisory Committee on Safety of Medicinal Products (ACSoMP) also evaluated the evidence and concluded that the Risk Management Plan for semaglutide should be revised to include NAION as a potential risk, including any required additional pharmacovigilance activities
While most nausea from GLP-1 therapies is self-limited, serious adverse events such as pancreatitis, severe dehydration, or gallbladder disease require immediate attention and possibly discontinuation of the medication
For acne, improvement may begin in about 8 to 12 weeks
Second, the rules shifted recently: after the FDA declared the semaglutide shortage resolved in early 2025, the special allowances that let pharmacies widely compound semaglutide were phased out over that year